Exploratory Study for Allergy Relief Onset


The purpose of the study is to explore the onset of effect of an antihistamine in a controlled environment.

Full Title of Study: “A Single-blind, Randomized, Placebo Controlled, Crossover Pilot Study to Evaluate the Onset of Action of an Antihistamine in Subjects Following Allergen Exposure in an Allergen Chamber”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Participant)
  • Study Primary Completion Date: May 27, 2016


  • Drug: Chlorpheniramine maleate (BAY X002134)
    • 4 mg tablet, single dose, orally
  • Drug: Placebo
    • placebo tablet, single dose, orally

Arms, Groups and Cohorts

  • Experimental: BAY X002134
    • Subjects will be given BAY X002134
  • Placebo Comparator: Placebo
    • Subjects will be given a placebo

Clinical Trial Outcome Measures

Primary Measures

  • The time to the meaningful relief, as defined by at least 15% of reduction from baseline in Total Symptom Score (TSS)
    • Time Frame: 4 hours

Secondary Measures

  • Number of patients with adverse events as a measure of safety
    • Time Frame: 3 month

Participating in This Clinical Trial

Inclusion Criteria

  • Ambulatory healthy male and female subjects between 18 to 65 years of age inclusive;
  • Self-reported to have seasonal allergic rhinitis for at least 2 years prior
  • Documented positive skin prick test response to common ragweed (ambrosia artemisiifolia) pollen; prick with wheal > 4mm larger than the diluent within the previous 12 months
  • Total Symptom Score (TSS) ≥ 40 mm at the 90 or 120 minute time point during one of the Priming Visits and at 90 or 120 minute time points during ragweed challenge Symptom Induction Phase of each Treatment Visit;
  • Body Mass Index (BMI) in the range of 18 to 30 kg/m2
  • Female subjects of childbearing potential must be using a medically acceptable form of birth control for at least 1 month prior to screening (3 months on oral contraceptives), e.g., oral or patch contraceptives, intrauterine device, injectable contraceptive (e.g. Depo-Provera®), or a double barrier and have a negative pregnancy test at Screening and prior to IMP administration on Day 1 and Day 7 ± 1 day. Female subjects of non-childbearing potential must be amenorrheic for at least two years or had a hysterectomy and/or bilateral oophorectomy

Exclusion Criteria

  • Evidence or self-reported history of significant medical condition which, in the judgment of the investigator, is a contraindication to the use of chlorpheniramine, or might interfere with the trial. These may include thyroid disease (e.g., hyperthyroidism, hypothyroidism), uncontrolled diabetes mellitus, coronary heart disease, ischemic heart disease , symptomatic prostatic hypertrophy, bladder neck obstruction, hepatic insufficiency, narrow-angle glaucoma, pyloroduodenal obstruction, or stenosing peptic ulcer;
  • Known allergy to chlorpheniramine, dexchlorpheniramine, or any of its inactive ingredients
  • Self-reported non-responders (lack of therapeutic effect) to antihistamines
  • Administration of epinephrine is contra-indicated;
  • Current use of oral steroids, including prednisone and prednisolone;
  • Females who are pregnant or lactating
  • A history of anaphylaxis to ragweed allergen
  • Subjects with a history of asthma, lower respiratory tract disease, emphysema or chronic bronchitis; At the discretion of the investigator, subjects with self-reported mild intermittent asthma or exercise induced asthma may be included.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Bayer
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Bayer Study Director, Study Director, Bayer

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.